Researchers found that estrogen inhibits a protein called MLK3 that causes normal cell death. Blocking MLK3 leads to uncontrolled growth of cancer cells and resistance to chemotherapy.
Researchers from Loyola University Health System and three other centers reported the findings in the journal Cancer Research.
"This could give us a new angle to treating breast cancer," said senior author Ajay Rana, PhD, a professor in the Department of Pharmacology at Loyola University Chicago Stritch School of Medicine.
About 60 percent of all breast cancers are estrogen-positive or progesterone-positive. This means the cancer cells have receptors for the female hormones estrogen and progesterone. Consequently, the hormones fuel the tumor's growth.
In laboratory experiments, researchers found that in estrogen-positive and progesterone-positive cancer cells, there is a reduction in the activity of MLK3. Consequently, cells can continue growing, changing and developing resistance to chemotherapy. "Cancer cells are very smart," Dr. Rana said.
By contrast, Dr. Rana's team found that MLK3 activity was much higher in estrogen-negative and progesterone-negative cancer cells.
The next step, Dr. Rana said, is to look for a drug that would overcome the inhibitory effect of estrogen on MLK3. Such a drug would be taken in combination with chemotherapy drugs.
Loyola co-authors are Velusamy Rangasamy, PhD (first author); Rajakishore Mishra, PhD; Suneet Mehrotra, PhD; Gautam Sondarva, PhD, Rajarshi S.Ray, PhD and Basabi Rana, PhD. Other co-authors are Arundhati Rao, MD, of Scott and White Hospital in Temple, Tx and Malay Chatterjee, PhD of Jadavpur University in Kolkata, India. Basabi Rana and Ajay Rana also are affiliated with Edward Hines Jr. VA Hospital.
TAG : estrogen fuels , breast cancers , breast tumors
From : medicalnewstoday.com
0 ความคิดเห็น:
แสดงความคิดเห็น